Assessment of quality of life in patients with permanent hypoparathyroidism receiving conventional treatment
Introduction Patients with permanent hypoparathyroidism suffer from multiple complaints and are exposed to long-term complications that might compromise their well-being. The aim of this study was to assess the quality of life (QoL) in patients with permanent hypoparathyroidism receiving conventional therapy and to determine the associated factors. Methods This was a cross-sectional matched case-control study including 53 patients with permanent hypoparathyroidism and 53 matched controls. Biochemical blood parameters (calcium, phosphate, albumin, magnesium, 25-hydroxy-vitamin D, creatinine, TSH, and PTH) and 24-hours calciuria were measured in patients with hypoparathyroidism. QoL was assessed in all participants using the Short Form 36 Health Survey (SF-36). Results The study included 53 patients (41 women and 12 men) with hypoparathyroidism receiving conventional therapy.Their mean age was 52.8 ± 16.5 years. In comparison with controls, patients with hypoparathyroidism had significantly lower scores in all eight domains of SF-36 (p < $ 10^{− 3} $). Patients with poor socioeconomic conditions had lower SF-36 scores than those with good conditions.The etiology of hypoparathyroidism, the disease duration, the control of the disease, and the body mass index did not significantly interfere with SF-36 scores. SF-36 total score was negatively correlated with age (r=-0.619, p < $ 10^{− 3} $) and symptoms of hypocalcemia (r=-0.284, p = 0.039), and positively correlated with creatinine clearance (r = 0.559, p < $ 10^{− 3} $), magnesium level (r = 0.345, p = 0.011), and 25 hydroxy-vitamin D level (r = 320, p = 0.021). No significant correlations were found between SF-36 scores and other biological parameters such as calcemia, phosphatemia, phosphocalcic product, PTH, TSH, and calciuria. Conclusion Patients with permanent hypoparathyroidism had impairment in their QoL. Age, socioeconomic conditions, renal function, magnesium level, and 25 hydroxy-vitamin D level may interfere in the decline of the QoL of these patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal of diabetes & metabolic disorders - 22(2023), 2 vom: 15. Sept., Seite 1617-1623 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cherchir, Faten [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Calcium level |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Tehran University of Medical Sciences 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s40200-023-01292-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053700945 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053700945 | ||
| 003 | DE-627 | ||
| 005 | 20231111064655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40200-023-01292-4 |2 doi | |
| 035 | |a (DE-627)SPR053700945 | ||
| 035 | |a (SPR)s40200-023-01292-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cherchir, Faten |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of quality of life in patients with permanent hypoparathyroidism receiving conventional treatment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Tehran University of Medical Sciences 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Introduction Patients with permanent hypoparathyroidism suffer from multiple complaints and are exposed to long-term complications that might compromise their well-being. The aim of this study was to assess the quality of life (QoL) in patients with permanent hypoparathyroidism receiving conventional therapy and to determine the associated factors. Methods This was a cross-sectional matched case-control study including 53 patients with permanent hypoparathyroidism and 53 matched controls. Biochemical blood parameters (calcium, phosphate, albumin, magnesium, 25-hydroxy-vitamin D, creatinine, TSH, and PTH) and 24-hours calciuria were measured in patients with hypoparathyroidism. QoL was assessed in all participants using the Short Form 36 Health Survey (SF-36). Results The study included 53 patients (41 women and 12 men) with hypoparathyroidism receiving conventional therapy.Their mean age was 52.8 ± 16.5 years. In comparison with controls, patients with hypoparathyroidism had significantly lower scores in all eight domains of SF-36 (p < $ 10^{− 3} $). Patients with poor socioeconomic conditions had lower SF-36 scores than those with good conditions.The etiology of hypoparathyroidism, the disease duration, the control of the disease, and the body mass index did not significantly interfere with SF-36 scores. SF-36 total score was negatively correlated with age (r=-0.619, p < $ 10^{− 3} $) and symptoms of hypocalcemia (r=-0.284, p = 0.039), and positively correlated with creatinine clearance (r = 0.559, p < $ 10^{− 3} $), magnesium level (r = 0.345, p = 0.011), and 25 hydroxy-vitamin D level (r = 320, p = 0.021). No significant correlations were found between SF-36 scores and other biological parameters such as calcemia, phosphatemia, phosphocalcic product, PTH, TSH, and calciuria. Conclusion Patients with permanent hypoparathyroidism had impairment in their QoL. Age, socioeconomic conditions, renal function, magnesium level, and 25 hydroxy-vitamin D level may interfere in the decline of the QoL of these patients. | ||
| 650 | 4 | |a Hypoparathyroidism |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Quality of life |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Calcium level |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a PTH |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Vitamin D |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Magnesium |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Oueslati, Ibtissem |0 (orcid)0000-0002-4278-9447 |4 aut | |
| 700 | 1 | |a Yazidi, Meriem |4 aut | |
| 700 | 1 | |a Chaker, Fatma |4 aut | |
| 700 | 1 | |a Chihaoui, Melika |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of diabetes & metabolic disorders |d London : BioMed Centra, 2012 |g 22(2023), 2 vom: 15. Sept., Seite 1617-1623 |w (DE-627)SPR033819432 |w (DE-600)2680289-2 |x 2251-6581 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:2 |g day:15 |g month:09 |g pages:1617-1623 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40200-023-01292-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 2 |b 15 |c 09 |h 1617-1623 | ||